Literature DB >> 11480103

Gender differences in depression associated with neurologic illness: clinical correlates and pharmacologic response.

C G Okiishi1, S Paradiso, R G Robinson.   

Abstract

Functional depression (i.e., depression without neuropathology) occurs approximately twice as often in women as in men. A review of the literature from the period 1966-1999 on the prevalence, clinical correlates, and treatment of depression in neurologic disease revealed a female preponderance of depression in diffuse neurologic disease, including Alzheimer's disease. In focal neurologic disease, the data were consistent for men and women, with a 1:1 ratio. Treatment data on depression in neurologic disease are scant, with the exception of poststroke depression. Although gender-based outcome data on the treatment of functional depression reveal better tolerability and response to serotonin reuptake inhibitors in women than in men, this phenomenon cannot be generalized to depression in neurologic disease. Men seem to consistently respond better than premenopausal women to tricyclic antidepressants in both functional and neurologic disease. Understanding how gender influences depression in neurologic illness and its response to treatment is a necessary step to improve the specificity of psychiatric treatment for depression.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11480103

Source DB:  PubMed          Journal:  J Gend Specif Med        ISSN: 1523-7036


  2 in total

1.  Clinical correlates of apathy in patients recently diagnosed with Parkinson's disease: the ANIMO study.

Authors:  Esther Cubo; Julián Benito-León; Carlos Coronell; Diana Armesto
Journal:  Neuroepidemiology       Date:  2012-01-06       Impact factor: 3.282

2.  APOE genotype predicts depression in women with Alzheimer's disease: a retrospective study.

Authors:  Lisa Delano-Wood; Wes S Houston; Jennifer A Emond; Natalie L Marchant; David P Salmon; Dilip V Jeste; Leon J Thal; Mark W Bondi
Journal:  Int J Geriatr Psychiatry       Date:  2008-06       Impact factor: 3.485

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.